Use of the immunopotentiator N-acetyl-glucosamine-N-acetylmuramyl dipeptide during triple anti-Helicobacter pylori therapy

Terapevticheskii Arkhiv

Volumn 84, Issue 12, 2012, Pages 66-70

  Konorev, M R ^a  

^a VITEBSK STATE MEDICAL UNIVERSITY   (Belarus)

Author keywords

Duodenal bulb ulcer; Eradication; Glucosaminylmuramyldipeptide; H. Pylori; Licopid

Indexed keywords

AMOXICILLIN; ANTIINFECTIVE AGENT; CLARITHROMYCIN; DRUG DERIVATIVE; GLUCOSAMINYLMURAMYL 2 ALANINE D ISOGLUTAMINE; GLUCOSAMINYLMURAMYL-2-ALANINE-D-ISOGLUTAMINE; IMMUNOLOGICAL ADJUVANT; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINE; OMEPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; ARTICLE; BREATH ANALYSIS; CLINICAL PROTOCOL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COST; DRUG EFFECT; DUODENUM ULCER; ECONOMICS; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; IMMUNOLOGY; INTESTINE MUCOSA; ISOLATION AND PURIFICATION; MALE; METHODOLOGY; MICROBIOLOGY; MIDDLE AGED; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ACETYLMURAMYL-ALANYL-ISOGLUTAMINE; ADJUVANTS, IMMUNOLOGIC; ADULT; AMOXICILLIN; ANTI-BACTERIAL AGENTS; BREATH TESTS; CLARITHROMYCIN; CLINICAL PROTOCOLS; DRUG COSTS; DUODENAL ULCER; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; OMEPRAZOLE; PROTON PUMP INHIBITORS; TREATMENT OUTCOME;

EID: 84875775913     PISSN: 00403660     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Blaser M.J. Hypothesis: the changing relationships of Helicobacter pylori and humans: implications for health and disease. J Infect Dis 1999; 179: 1523-1530. (Pubitemid 29246603)
2. Go M.F. Natural history and epidemiology of Helicobacter pylori infection. Aliment Pharmacol Ther 2002; 16 (Suppl. 1): 3-15. (Pubitemid 41759561)
3. Megraud F., Brassens-Rabbe M.P., Denis F. Seroepidemiology of Campylobacter pylori infection in various populations. J Clin Microbiol 1989; 27: 1870-1873. (Pubitemid 19182896)
4. Pimanov S.I., Makarenko E. V., Voropaeva A. V. et al. Prerequisites for empirical eradication therapy in patients with duodenal ulcer study in Belarus. Helicobacter 2003; 8: 475.
5. Graham D. Y., Opekun A., Lew G.M. Ablation of exaggragated meal-stimulated gastrin release in duodenal ulcer patients after clearance of Helicobacter pylori infection. Am J Gastroenterol 1990; 85: 394-398. (Pubitemid 20140612)
6. Fan X. G., Yakoob J., Fan X.J., Keling P. W. Enchanced T-helper 2 lymphocyte responses: immune mechanism of helicobacter pylori infection. Ir J Med Sci 1996; 165 ( 1): 37-39.
7. Beigler-Bompadre M., Moos V., Belogobva E. et al. Modulation of the CD4+ T-cell response by helicobacter pylori depends on known virulence factors and bacterial cholesterol and cholesterol α-glucoside content. J Infect Dis 2011; 204 ( 9): 1339-1348.
8. Kido M., Tanaka J., Aoki N. et al. Helicobacter pylori promotes the production of thymic stromal lymphopoietin by gastric epithelial cells and induces dendritic cell-mediated inflammatory Th2 responses. Infect Immun 2010; 78 ( 1): 108-114.
9. Rathbone B.J., Wyatt J.I., Worsley B. W. et al. Systemic and local antibody responses to gastric Campylobacter pyloridis in non-ulcer dyspepsia. Gut 1986; 27: 642-647. (Pubitemid 16085548)
10. Perez-Perez. G.I., Dworkin B.M., Chodos J.E. et al. Campylobacter pyloriantibodies in humans. Ann Intern Med 1988; 109: 11-17.
11. Dunn B., Cohen H., Blaser M.J. Helicobacter pylori. Clin Microbiol Rev 1997; 10 (4): 720-741. (Pubitemid 27477732)
12. Karttunen R.A., Karttunen T.J., Yousfl M.M. et al. Expression of mRNA for interferon-gamma, interleukin-10, and interleukin-12 (p40) in normal gastric mucosa and in mucosa infected with Helicobacter pylori. Scand J Gastroenterol 1997; 32: 22-27. (Pubitemid 27026462)
13. Versalovic J. Helicobacter pylori: Pathology and Diagnostic Stratedies. Am J Clin Pathol 2003; 119 (3): 403-412. (Pubitemid 37047864)
14. Micu G., Stǎ;niceanu F., Zurac S. et al. The influence of Helicobacter pylori presence on the immunophenotype of inflammatory infiltrate in gastric diseases. Rom J Intern Med 2011; 49 ( 1): 45-54.
15. Garhart C.A., Heinzel F.P., Czinn S.J. et al. Vaccine-induced reduction of Helicobacter pylori colonization in mice is interleukin-12 dependent but gamma interferon and inducible nitric oxide synthase independent. Infect Immun 2003; 71: 910-921. (Pubitemid 36150787)
16. Becher D., Deutscher M.E., Simpfendorfer KR. et al. Local recall responses in the stomach involving reduced regulation and expanded help mediate vaccine-induced protection against Helicobacter pylori in mice. Eur J Immunol 2010; 40 ( 10): 2778-2790.
17. Malfertheiner P., Megraud F., O'Morain C.A. et al. Management of Helicobacter pylori infection - the Maastricht-IV / Florence Consensus Report. Gut 2012; 61: 646-664.
18. Box G.E., Hunter W.G., Hunter J.S. Statistics for Experimenters: An introduction to design, data analysis, and model building. New York: John Wiley and Sons 1978.
19. Tytgat G.N. The Sydney system, endoscopic division: endoscopic appearance in gastritis. J Gastroenterol Hepatol 1991; 6 ( 3): 223-234.
20. Price A.B. The Sydney system: Histological division. J Gastroenterol Hepatol 1991; 6 ( 3): 209-222.
21. Dixon M., Genta R.M., Yardley J.H. et al. Classification and grading of gastritis. Am J Surg Pathol 1996; 20: 1161-1181.
22. Chang C., Pan S., Lien Gi. et al. Investigation of the extent of gastric metaplasia in the duodenal bulb by using methylene blue staining. J Gastroenterol Hepatol 2001; 16 ( 7): 729-739.
23. Betty R. Essential medical statistics. 2nd ed. Kirkwood and Jonathan A. C. Sterne: Blackwell Science Ltd. 2003: 414-425.